Compare Stocks: APGN and EFHTU

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGN Apexigen	$0.39	$0.39	$0.33 ▼ $8.28	$9.57M	3.6	967,731 shs	N/A
EFHTU EF Hutton Acquisition Co. I	$10.10 -1.9%	$10.10	$9.95 ▼ $11.33	N/A	N/A	99,600 shs	800 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGN Apexigen	0.00%	0.00%	0.00%	0.00%	-18.09%
EFHTU EF Hutton Acquisition Co. I	0.00%	0.00%	0.00%	0.00%	0.00%

Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGN Apexigen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EFHTU EF Hutton Acquisition Co. I	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGN Apexigen	N/A	N/A	N/A	N/A
EFHTU EF Hutton Acquisition Co. I	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGN Apexigen	N/A	N/A	N/A	N/A	($0.09) per share	N/A
EFHTU EF Hutton Acquisition Co. I	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGN Apexigen	-$32.07M	N/A	0.00	∞	N/A	N/A	-614.82%	-133.30%	N/A
EFHTU EF Hutton Acquisition Co. I	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGN Apexigen	N/A	N/A	N/A	N/A	N/A
EFHTU EF Hutton Acquisition Co. I	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGN Apexigen	N/A	0.82	0.82
EFHTU EF Hutton Acquisition Co. I	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
APGN Apexigen	13.65%
EFHTU EF Hutton Acquisition Co. I	N/A

Insider Ownership

Company	Insider Ownership
APGN Apexigen	19.20%
EFHTU EF Hutton Acquisition Co. I	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APGN Apexigen	11	24.86 million	20.09 million	Not Optionable
EFHTU EF Hutton Acquisition Co. I	N/A	N/A	N/A	Not Optionable

APGN and EFHTU Headlines

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Company Descriptions

Apexigen

NASDAQ:APGN

Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.

EF Hutton Acquisition Co. I

NASDAQ:EFHTU

EF Hutton Acquisition Corporation I offers effecting a merger, stock capital exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the consumer and retail industry. The company was founded in 2022 and is based in Hingham, Massachusetts.

Compare Stocks